Recent Developments
Major players operating in the global shigella vaccines market are focused on adopting partnership strategies to expand their product portfolio. For instance, in January 2017, Prokarium collaborated with Probiomed for the manufacture of orally-administrated vaccine to prevent diarrhea.
Global Shigella Vaccines Market: Drivers
High prevalence of shigellosis is expected to propel growth of the global shigella vaccines market over the forecast period. For instance, in 2013, the average annual incidence of shigellosis in the U.S. was around 5 cases per 100,000 individuals, according to the Centers for Disease Control and Prevention.
Moreover, R&D of new products is also expected to propel growth of the global shigella vaccines market over the forecast period. For instance, in March 2017, Hilleman Laboratories, a non-profit organization, partnered with National Institute of Cholera and Enteric Disease for the development and commercialization of vaccines against Shigella by 2024. Similarly, in October 2019, The European Vaccine Initiative partnered with Hilleman Laboratories for R&D of new shigella vaccine.
𝐓𝐨 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐋𝐚𝐭𝐞𝐬𝐭 𝐂𝐨𝐯𝐢𝐝𝟏𝟗 𝐈𝐦𝐩𝐚𝐜𝐭 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 @ https://www.coherentmarketinsights.com/insight/request-sample/1110
Global Shigella Vaccines Market: Opportunities
R&D of new products is expected to offer lucrative growth opportunities for players in the global shigella vaccines market. For instance, in September 2019, LimmaTech Biologics AG and GlaxoSmithKline plc. initiated Phase I/II clinical trial of 4-valent candidate vaccine in Kenya to prevent diarrheal disease cause due to Shigella in the developing economies.
Moreover, funding for R&D is also expected to offer lucrative growth opportunities for players in the global shigella vaccines market. For instance, in September 2019, Horizon2020, a research and innovation program from the European Union granted US$ 9,470,750 to EveliQure Biotechnologies for R&D of its ShigETEC vaccine.
Market Trends
North America is expected to witness significant growth in the global shigella vaccines market, owing to funding for R&D of new vaccines. For instance, in August 2017, the National Institute of Allergy and Infectious Diseases granted US$ 2.47 million to University of Maryland School of Medicine for R&D of vaccine against Shigella and Enterotoxigenic Escherichia coli for the treatment of diarrheal disease.
𝐓𝐨 𝐆𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐇𝐞𝐫𝐞 @ https://www.coherentmarketinsights.com/insight/request-pdf/1110
Recent strains of Shigella bacteria have demonstrated reduced susceptibility to ciprofloxacin. For instance, in April 2017, the Centers for Disease Control and Prevention warned against the reduced susceptibility of recent strains of Shigella bacteria to ciprofloxacin, which is one of the main antibiotics recommended by WHO for the treatment of shigellosis.
Global Shigella Vaccines Market: Competitive Landscape
Major players operating in the global shigella vaccines market include, GlaxoSmithKline plc., MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd., Novartis AG.
Global Shigella Vaccines Market: Key Developments
Major players operating in the global shigella vaccines market are focused on adopting partnership strategies to expand their product portfolio. For instance, in June 2016, Immuron entered into an agreement with the U.S Army’s biomedical research lab-Walter Reed Army Institute of Research to produce Shigella vaccine.
𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓𝐨 𝐀𝐯𝐚𝐢𝐥 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐅𝐥𝐚𝐭 𝟑𝟎% 𝐎𝐅𝐅
𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐓𝐨 𝐀𝐜𝐜𝐞𝐬𝐬 𝐅𝐮𝐥𝐥 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 @ https://www.coherentmarketinsights.com/insight/buy-now/1110
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Shigella Vaccines Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Shigella Vaccines Industry Impact
Chapter 2 Global Shigella Vaccines by Types, Applications, and Top Regions and Countries
2.1 Global Shigella Vaccines (Volume and Value) by Type
2.3 Global Shigella Vaccines (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Shigella Vaccines Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Shigella Vaccines Market Analysis
Chapter 6 East Asia Shigella Vaccines Market Analysis
Chapter 7 Europe Shigella Vaccines Market Analysis
Chapter 8 South Asia Shigella Vaccines Market Analysis
Chapter 9 Southeast Asia Shigella Vaccines Market Analysis
Chapter 10 Middle East Shigella Vaccines Market Analysis
Chapter 11 Africa Shigella Vaccines Market Analysis
Chapter 12 Oceania Shigella Vaccines Market Analysis
Chapter 13 South America Shigella Vaccines Market Analysis
Chapter 14 Company Profiles and Key Figures in Shigella Vaccines Business
Chapter 15 Global Shigella Vaccines Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology
Continued….
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837